LID.L Regulatory News (LID)

23 Feb 2007 07:00

For immediate release 23 February 2007 LiDCO Group Plc ("the Company") Trading Update

LiDCO, the UK based, AIM-quoted cardiovascular monitoring company, today provides an update on trading for the year ending 31 January 2007.

LiDCO announces that sales to 31 January 2007 were ‚£3.44m and the cash balance as at 31 January 2007 was ‚£1.47m.

The Company flagged in its November announcement that 2006 was a tough year, particularly in the US. Encouragingly, sales in the US since the beginning of 2007 have been strong with orders for 18 LiDCOplus Monitors from 4 centres already placed. Notably, LiDCO secured an important initial order for 8 LiDCOplus Monitors from Harborview Medical Center, Seattle, a primary teaching site for the University of Washington School of Medicine and a reference hospital for the Pacific Northwest region.

A significant achievement in year to January 2007 was that, despite there being an NHS capital freeze for a substantial part of the year, the Company increased UK sales revenue by 31% over the prior year.

- ENDS -

For more information please contact:

LiDCO Group Plc Tel: +44 (0)20 7749 1500 Terry O'Brien - Chief Executive

Buchanan Communications Tel: +44 (0)20 7466 5000 Tim Anderson, James Strong Notes for EditorsAbout LiDCO Group Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base.

The Company's manufacturing facility is in Hoxton, London and its current products are:

- LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;

- LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:

The Company has now achieved registration of its products in 14 markets in Europe, the USA, Brazil and Japan. It sells direct in the UK and USA, and elsewhere through a worldwide network of specialty critical care distributors.